Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Carcinoma, Ovarian Epithelial 1

Interventions

fludarabine phosphate 19Cyclophosphamide 18Tacrolimus 17Peripheral Blood Stem Cell Transplantation 17Mycophenolic Acid 17Antilymphocyte Serum 14Busulfan 13Whole-Body Irradiation 12Methotrexate 11Cyclosporine 11Melphalan 7mogamulizumab 6Methylprednisolone 6Etoposide 6Bexarotene 6Sirolimus 5Radiotherapy 5Flow Cytometry 5Filgrastim 5sargramostim 4pembrolizumab 4Vorinostat 4Transplantation 4Therapeutics 4Rituximab 4Lenalidomide 4Brentuximab Vedotin 4Alemtuzumab 4thymoglobulin 3romidepsin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell, Cutaneous × Depsipeptides × Clear all
NCT00106431 2019-10-30

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Celgene

Phase 2 Completed
102 enrolled 15 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡